- Hearing loss afflicts 15 percent of U.S. adults and is an overlooked public health epidemic.
- Traditional hearing aids and cochlear implants are limited solutions.
- Medical start-ups, including Decibel Therapeutics and Frequency Therapeutics, are pursuing drug breakthroughs for hearing loss, backed by venture capital and pharmaceutical firms.
Maybe you sat too close to those ginormous stage speakers at a Jefferson Airplane concert back in the day. Or your earbuds have been turned up way too loud for far too long. Or you're just growin' old.
Those are among the various reasons why tens of millions of people — including 15 percent of the adult population in the United States — experience hearing loss, now a public health epidemic.
Hearing aids and cochlear implants that amplify sounds are traditional, if limited, solutions, but now breakthrough medical remedies are in the works. Currently, several biotechnology companies are developing novel drug therapies that promise to actually repair inner-ear damage and restore normal hearing.
As with many of the human body's systems, from eyesight to libido, hearing naturally declines with age. But ever since the industrial revolution and the rise of clanky machines, the volume of everyday life has reached cacophonous proportions and contributed to hearing loss — and not just with old folks.
According to statistics compiled by the National Institutes of Health, about three out of every 1,000 children in the United States are born with a detectable level of hearing loss in one or both ears. One in eight Americans (30 million) age 12 years or older has hearing loss in both ears. Close to 38 million Americans age 18 and over report some trouble hearing. Worldwide, hearing loss afflicts 360 million people.
There are existing drugs for effectively treating middle-ear infections, "but nothing that works on the cochlea," said Paula Cobb, executive vice president of corporate development at Decibel Therapeutics, a Boston-based start-up launched in 2015 with $52 million in venture capital from biotech investment firm Third Rock Ventures and SR One, the VC arm of pharma giant GlaxoSmithKline.
More from Modern Medicine:
Cobb was referring to the very small spiral tube encased within the inner ear, which contains the nerve endings that transmit sound vibrations from the middle ear to the auditory nerve. "It's a poorly understood organ in the middle of one of the hardest bones in the body," Cobb said. Noise-induced damage to the nearly 15,000 tiny hair cells and neurons in the cochlea or to the auditory nerve is by far the leading cause of what's known as sensorineural hearing loss.
In order to develop drugs to accurately target either the auditory nerve or hair cells, Decibel's researchers delve into the anatomy of the inner ear, down to the cellular level. "If you don't do the fundamental work to understand what you're trying to achieve and actually getting the drug in there, it's shooting in the dark in terms of doing clinical development," Cobb said.
In late November, Decibel entered into a partnership with Regeneron, a biotech drug developer in Tarrytown, New York. Besides accessing Regeneron's robust research tools, particularly in genetics, Decibel also will benefit from its financial support. Decibel, however, retains worldwide development and commercialization rights to any products discovered in the collaboration and will pay Regeneron tiered royalties based on net sales.
Just north of Boston, in Woburn, Massachusetts, Frequency Therapeutics was founded in 2015 by biomedical engineers Bob Langer of MIT and Jeffrey Karp of Harvard Medical School. Frequency's focus is on developing small molecule drugs that activate dormant progenitor cells, types of stem cells, to repair damaged cochlear hair cells and restore hearing. "It's important to do it in an organic way, as the body had originally designed it to be done," said David Lucchino, co-founder, president and CEO of Frequency.
He likens the process to immunotherapy, which activates the body's immune system, an increasingly successful approach in treating cancer. "We are reactivating the body's system and letting it do the work," Lucchino said.
Delivering its drugs to the hard-to-reach hair cells has been a limiting factor. One of Frequency's key breakthroughs was figuring out how to grow cochlear tissue outside the body to do proper drug screening, thereby allowing researchers to identify the small molecules that have this effect. "The challenge is to translate that to inside the body and show you can get the biological response in humans," Lucchino said. "That's what we're doing in the clinic now."
In December the company announced the successful completion of a Phase 1 human study of FX-322, Frequency's lead progenitor cell activation drug, demonstrating its safety and tolerability. "We expect to start a Phase 2 clinical study in the second half of 2018," Lucchino said. The company has previously raised $32 million in Series A funding from CoBro Ventures, Morningside Ventures, Alexandria Real Estate Equities and other investors, and expects to begin a Series B round later this year.
Two publicly traded companies are making noise in this space. Auris Medical, a Swiss biopharmaceutical firm, is in advanced clinical development of drugs to treat inner-ear hearing loss and tinnitus, the condition of ringing or buzzing in the ears.
San Diego-based Otonomy, founded in 2008, has taken a three-pronged approach in its drug R&D. The first targets chemotherapy-induced hearing loss, a side effect of some cancer-fighting medicines, in particular platinum-based agents. "We've conducted preliminary clinical research in that area and are working to develop a product," said CEO and president David Weber.
Otonomy also concentrates on treating sensorineural destruction of the ribbon synapse connections that connect hair cells to the auditory nerve bundle, which results in earlier-stage hearing loss. That condition might not be profound enough to be detected in a hearing test, Weber said, "but is contributing to what I'll call 'cocktail noise' hearing loss: You can't distinguish sounds at a cocktail party where there's a lot of background sound."
Otonomy has developed a drug therapy, which has shown proof of concept in an animal model, to restore synapse connections and functional hearing. Otonomy also is developing medicines to restore the loss of hair cells. All three programs are in the preclinical stages, Weber said, and he declined to predict how soon any would move to the human clinical trial stage.
Although one or more drugs that might temporarily or permanently repair inner-ear damage and restore hearing loss is still several years away from commercial availability, Decibel's Cobb offered some sound advice on how to prevent hearing problems. "The best way to handle noise damage," she said, "is to wear earplugs."
— Bob Woods, special to CNBC.com